Как избежать опасности гипогликемии - одного из важнейших осложнений терапии сахарного диабета 2-го типа? Роль ингибиторов ДПП-4
Аннотация
Список литературы
1. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
2. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
3. Shichiri M., Kishikawa H., Ohkubo Y., Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000;23:Suppl 2:21-29.
4. Nathan D.M., Buse J.B., Davidson M.B. et al. American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
5. Dejager S., Schweizer A. Minimizing the Risk of Hypoglycemia with Vildagliptin: Clinical Experience, Mechanistic Basis, and Importance in Type 2 Diabetes Management. Published online: February 8, 2011.
6. Gangji A.S., Cukierman T., Gerstein H.C. et al. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007;30:389-394.
7. Fravel M.A., McDanel D.L., Ross M.B. et al. Special considerations for treatment of type 2 diabetes mellitus in the elderly. Am J Health Syst Pharm 2011;68:6:500-509.
8. Miller D.R., Finckel G., Lafrance J.-P. et al. Hypoglycaemia and risk of myocardial infarction in U.S. veterans with Diabetes. EASD 2009. Diabetologia 2009;52:Suppl 1:63.
9. Alvarez G.F., Tofe P.S., Krishnarajah G. et al. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAPDM) Study. Diabetes Obes Metab 2008;10:Suppl 1:25-32.
10. Leese G.P., Wang J., Broomhall J. et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003;26:1176-1180.
11. Hammer M., Lammert M., Mejias S.M. et al. Costs of managing severe hypoglycaemia in three European countries. J Med Econ 2009;12:281-290.
12. Patel A., MacMahon S., Chalmers J. et al. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572.
13. Gerstein H.C., Miller M.E., Byington R.P. et al. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559.
14. Duckworth W., Abraira C., Moritz T. et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139.
15. Skyler S., Bergenstal R., Bonow R. et al. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. Diabetes Care 2009;32:1:187-192.
16. Ray K.K., Seshasai S.R., Wijesuriya S. et al. Effect of Intensive Control of Glucose on Cardiovascular Outcomes and Death in Patients With Diabetes Mellitus: A Meta-analysis of Randomised Controlled Trials. Lancet 2009;373:1765-1772.
17. Turnbull F.M., Abraira C., Anderson R.J. et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52:11:2288-2298.
18. Дедов И.И., Шестакова М.В., Аметов А.С. и др. Консенсус совета экспертов Российской ассоциации эндокринологов (РАЭ) по инициации и интенсификации сахарснижающей терапии сахарного диабета 2-го типа (проект). Сахарный диабет 2011;1:98-108.
19. Ahrén B., Gomis R., Standl E. et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004;27:2874-2880.
20. Ferrannini E., Fonseca V., Zinman B. et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009;11:157-166.
21. Matthews D.R., Dejager S., Ahren B. et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 2010;12:780-789.
22. Garber A.J., Foley J.E., Banerji M.A. et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab 2008;10:1047-1056.
23. Fonseca V., Schweizer A., Albrecht D. et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007;50:1148-1155.
Для цитирования:
., . Как избежать опасности гипогликемии - одного из важнейших осложнений терапии сахарного диабета 2-го типа? Роль ингибиторов ДПП-4. Проблемы Эндокринологии. 2011;57(3):48-52. https://doi.org/10.14341/probl201157348-52
For citation:
Pavlova M.G., Zilov A.V. How can we avoid the danger of hypoglycemia, one of the most serious complications of therapy of type 2 diabetes mellitus? The role of DPP-4 inhibitors. Problems of Endocrinology. 2011;57(3):48-52. (In Russ.) https://doi.org/10.14341/probl201157348-52